An interview with Dr. Jennifer K. Lue, Assistant Professor of Medicine, Center for Lymphoid Malignancies, Division of Hematology and Oncology, Columbia University Irving Medical Center
Treating CLL with CALQUENCE® (acalabrutinib)
April 23rd 2021, 9:00pm
Imbruvica combined with ublituximab improved overall response rate and progression-free survival for relapsed/refractory high-risk chronic lymphocytic leukemia with minimal residual disease negativity.
April 22nd 2021, 9:00pm
Final analysis of a phase 3 study demonstrates a tolerable toxicity profile for Gazvya in combination with chemotherapy for patients with ether first-line or relapsed/refractory chronic lymphocytic leukemia.
April 16th 2021, 12:00pm
Navigating life with blood cancer
March 17th 2021, 12:00pm
An interview with Dr. Jennifer K. Lue, Assistant Professor of Medicine, Center for Lymphoid Malignancies, Division of Hematology and Oncology, Columbia University Irving Medical Center.
March 3rd 2021, 7:00pm
Patients treated with Imbruvica plus TG-1101 had an overall response rate of 83% compared with 65% in those treated with Imbruvica alone.
February 19th 2021, 9:30pm
February 19th 2021, 4:00pm
From the death of Bill Ludwig, the first patient to receive CAR-T cell therapy to treat his end-stage CLL, to a letter to the President urging him to grant patients with cancer and survivors priority access to the COVID-19 vaccine, here’s what’s happening in the cancer space this week.
February 19th 2021, 1:00pm
February 15th 2021, 4:00pm
The NCCN has updated its recommendations for chronic lymphocytic leukemia and small lymphocytic lymphoma to now include Brukinsa as a first- and second-line therapy in a subgroup of patients.
February 2nd 2021, 9:30pm
Inaccurate Information on Cancer Diagnosis and Treatment Common on Social Media Sites
Small-Town Cancer Team, Big Success
Grief Is Like Swimming
Rick Aiello Dies From Pancreatic Cancer, FDA Approves First Drug to Treat Lymphoma in Dogs and More
